Your session is about to expire
← Back to Search
Bortezomib + Gemcitabine for B-Cell Lymphoma
Study Summary
This trial is studying the side effects and best dose of bortezomib and gemcitabine hydrochloride when given together with rituximab to treat patients with B-cell non-Hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have taken any experimental medications within the last two weeks before joining the study.You have a severe medical or mental health condition that could make it difficult for you to take part in this study.You are allergic to bortezomib, boron, or mannitol.You are not eligible if you have an active condition affecting your brain or spinal cord.You are able to perform daily activities without much difficulty or assistance, with a performance level of at least 60%.You are expected to live for at least 3 more months.
- Group 1: Treatment (bortezomib, gemcitabine hydrochloride, rituximab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide some background information on rituximab testing?
"There are almost one thousand ongoing clinical trials researching rituximab, with 262 of those in the final stage. Rituximab studies are mostly based out of Shanghai but there are over 45000 other locations conducting research for this medication."
What are some of the primary conditions that rituximab is used to treat?
"The most common treatment for diffuse large b-cell lymphoma (dlbcl) is rituximab. Rituximab can also help patients with small cell lung cancer (sclc), head and neck carcinoma, and cervical cancers manage their condition."
How many test subjects are participating in this research?
"This specific trial is no longer recruiting patients, as it was last updated on February 28th, 2022. If you are seeking other trials, there are 1810 active lymphoma studies and 992 active rituximab studies that are looking for participants."
Are researchers still looking for people to participate in this trial?
"This study is not looking for new participants at the moment. It was first posted on 6/29/2005, with the latest update on 2/28/2022. For those searching for similar studies, 1810 clinical trials are actively recruiting patients with lymphoma and 992 trials involving rituximab are also admitting new patients."
Share this study with friends
Copy Link
Messenger